The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial
Abstract
Background Calcineurin inhibitors (CNIs) reduce short-term kidney transplant failure, but might contribute to transplant failure in the long-term. The role of alemtuzumab (a potent lymphocyte-depleting antibody) as an induction treatment followed by an early reduction in CNI and mycophenolate exposure and steroid avoidance, after kidney transplantation is uncertain. We aimed to assess the efficacy and safety of alemtuzumab-based induction treatment compared with basiliximab-based induction treatment in patients receiving kidney transplants.Methods For this randomised trial, we enrolled patients aged 18 years and older who were scheduled to receive a kidney transplant in the next 24 h from 18 transplant centres in the UK. Using minimised randomisation, we randomly assigned patients (1:1; minimised for age, sex, and immunological risk) to either alemtuzumab-based induction treatment (ie, alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids) or basiliximab-based induction treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone). Participants were reviewed at discharge from hospital and at 1, 3, 6, 9, and 12 months after transplantation. The primary outcome was biopsy-proven acute rejection at 6 months, analysed by intention to treat. The study is registered at ClinicalTrials.gov, number NCT01120028, and isrctn.org, number ISRCTN88894088.Findings Between Oct 4, 2010, and Jan 21, 2013, we randomly assigned 852 participants to treatment: 426 to alemtuzumab-based treatment and 426 to basiliximab-based treatment. Overall, individuals allocated to alemtuzumab-based treatment had a 58% proportional reduction in biopsy-proven acute rejection compared with those allocated to basiliximab-based treatment (31 [7%] patients in the alemtuzumab group vs 68 [16%] patients in the basiliximab group; hazard ratio (HR) 0·42, 95% CI 0·28-0·64; log-rank p<0·0001). We detected no between-group difference in treatment effect on transplant failure during the first 6 months (16 [4%] patients vs 13 [3%] patients; HR 1·23, 0·59-2·55; p=0·58) or serious infection (135 [32%] patients vs 136 [32%] patients; HR 1·02, 0·80-1·29; p=0·88). During the first 6 months after transplantation, 11 (3%) patients given alemtuzumab-based treatment and six (1%) patients given basiliximab-based treatment died (HR 1·79, 95% CI 0·66-4·83; p=0·25).Interpretation Compared with standard basiliximab-based treatment, alemtuzumab-based induction therapy followed by reduced CNI and mycophenolate exposure and steroid avoidance reduced the risk of biopsy-proven acute rejection in a broad range of patients receiving a kidney transplant. Long-term follow-up of this trial will assess whether these effects translate into differences in long-term transplant function and survival.Funding UK National Health Service Blood and Transplant Research and Development Programme, Pfizer, and Novartis UK.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, TA has been described only rarely when alemtuzumab is administered for rheumatoid arthritis [32], blood cancers [33], or transplantation [34], suggesting a disease specific and/or genetic background effect.”
From 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy (2019) · cites this paper as [34]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Wolfe, R. A., Ashby, V. B., Milford, E. L., OJO, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,370
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
The Natural History of Chronic Allograft Nephropathy
Nankivell, B. J., Borrows, R., Fung, C. L.-S., O’Connell, P. J., Allen, R. D. M., & Chapman, J. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020009 · Cited by 1,942
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
Kasiske, B. L., Zeier, M. G., Chapman, J. R., Craig, J. C., Ekberg, H., Garvey, C. A., Green, M. D., Jha, V., Josephson, M. A., KIBERD, B. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.377 · Cited by 1,734
Haas, M., Sis, B., Racusen, L. C., Solez, K., Glotz, D., Colvin, R. B., de Castro, M. C. R., David, D. S. R., David‐Neto, E., Bagnasco, S. M., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12590 · Cited by 1,349
Research works printed but not linked: 1
- Pascual, 2008, Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction, Am J Transplant, 8, 237
Cited by
Sorted by citations
Items 101–151 of 151
Evolution of Immunosuppressive Agents in Renal Transplantation: An Updated Review
Kumar, A. M. S., & Shrestha, B. M. (2016) · International Journal of Stem Cell Research and Transplantation · doi:10.19070/2328-3548-1600027 · Cited by 3
Kaplan, A. N., Young, J. H., Kandaswamy, R., Berglund, D. M., Knoll, B. M., Sieger, G. K., Cavert, W. P., Matas, A. J., & Obeid, K. M. (2020) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2020/8883183 · Cited by 3
Pradegan, N., Tolomeo, A. M., Ciccarelli, D., Cozzi, E., Vitiello, A., Zovi, A., & Gerosa, G. (2025) · Xenotransplantation · doi:10.1111/xen.70061 · Cited by 3
Induction Therapy and Therapeutic Antibodies
Nikolova, A., & Patel, J. K. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_570 · Cited by 3
Watson, C. J. E., & Clatworthy, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00018-8 · Cited by 3
Postrenal transplant infection: What is the effect of specific immunosuppressant agents?
Monlezun, D. J., John, M. M., Dortonne, I., Gaines, I., Carsky, K., Chernobylsky, D., Ferrin, P. C., Paramesh, A. S., Zhang, R., McDermott, C., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.05.056 · Cited by 3
Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis
Fernández‐Ruiz, M., & Aguado, J. M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.002 · Cited by 3
Lim, M. A., & Bloom, R. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00038-0 · Cited by 3
Simultaneous pancreas-kidney transplantation
Mosca, I., Sharples, E. J., Sinha, S., & Friend, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00012-5 · Cited by 3
Alemtuzumab Associated With Higher Mortality Than Basiliximab in Older Kidney Transplant Recipients
Guo, M., Rohan, V., Ladner, D. P., Friedewald, J. J., Cahan, J. G., & Dietch, Z. C. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.11.006 · Cited by 2
Chukwu, C., Kalra, P. A., Lowe, M., Poulton, K., Augustine, T., & Rao, A. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i1.111959 · Cited by 2
Zheng, Y., Guan, Y., Li, Z., Guo, G. Z. A. Y., & Ai, X. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002518 · Cited by 2
Shao, M., Tian, T., Zhu, X., Ming, Y., Iwakiri, Y., Ye, S., & Ye, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.19815 · Cited by 2
Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review
Naesens, M., Berger, S. P., Biancone, L., Crespo, M., Djamali, A., Hertig, A., Öllinger, R., Portolés, J. M., Zuckermann, A. O., & Pascual, J. (2016) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2016.09.001 · Cited by 2
Immunosuppression for pancreas allo-transplantation
Harriman, D. I., & Rogers, J. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00018-6 · Cited by 2
Alemtuzumab induction therapy in kidney transplantation
Dhaun, N., & Kluth, D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60430-5 · Cited by 2
Alemtuzumab induction therapy in kidney transplantation
Berghofen, A., Singer, T., Krüger, B., Krämer, B. K., & Benck, U. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60431-7 · Cited by 2
Personalized Anti-Rejection Therapy with Alemtuzumab for Kidney Transplant Recipients
Hesselink, D. A., Hullegie-Peelen, D. M., & van Vugt, L. K. (2022) · Pharmacogenomics · doi:10.2217/pgs-2022-0071 · Cited by 2
O’Connor, K. W., Bagnasco, S. M., Pruette, C. S., Goswami, E., & Charnaya, O. (2026) · Pediatric Transplantation · doi:10.1111/petr.70446 · Cited by 1
Alemtuzumab induction reduces acute rejection risk
Sidaway, P. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.143 · Cited by 1
BK Polyomavirus in Renal Transplantation
Johnson, A. (2014) · General Medicine Open Access · doi:10.4172/2327-5146.1000154 · Cited by 1
Induction Therapy in Pediatric Renal Transplant Recipients
Charnaya, O., Moudgil, A., & Puliyanda, D. P. (2023) · Springer eBooks · doi:10.1007/978-981-19-6909-6_9 · Cited by 1
Induction immunosuppression strategies and outcomes post-lung transplant: A single center experience
Narula, T., Alvarez, F., Abdelmoneim, Y., Erasmus, D. B., Li, Z., & Elrefaei, M. (2024) · Transplant Immunology · doi:10.1016/j.trim.2024.102081 · Cited by 1
Weight-based dosing of alemtuzumab: an ounce of prevention?
Augustine, J. J. (2017) · Transplant International · doi:10.1111/tri.12992 · Cited by 1
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Chambers, E. T., & Kirk, A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00019-x · Cited by 1
Steroid Avoidance in Low-Immunologic Risk Kidney Transplant Recipients: The New Normal?
Legendre, C. M. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.12.016 · Cited by 1
Stratta, R. J. (2015) · Clinical Transplantation · doi:10.1111/ctr.12543
Alemtuzumab induction therapy in kidney transplantation – Authors' reply
Haynes, R., Baigent, C., Landray, M., Harden, P., & Friend, P. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60432-9
Effetti collaterali delle bioterapie nella sclerosi multipla e nelle malattie correlate
Lepetit, M., & Laplaud, D. A. (2016) · EMC - Neurologia · doi:10.1016/s1634-7072(16)78802-7
Approaches to the Induction of Tolerance
Wood, K. J., & Geissler, E. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00021-8
Daloul, R., Gupta, S. D., & Brennan, D. C. (2017) · Current Transplantation Reports · doi:10.1007/s40472-017-0147-8
Induction Immunosuppression in Kidney Transplantation
Grinyo, J. M., & Bestard, O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00019-9
Prognostic immune markers for chronic allograft injury inrenal transplant recipients
Jham, S. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Kidney Transplant-Immunosuppression and Rejection
Lockridge, J., & Olyaei, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_4
Zhang, A. W., Zhang, B. D., Yaozhong, L., Mary, K., Paramesh, A. S., Joseph, B., Alper, B., Fred, T., Baudy, A. J., & Zhang, R. (2018) · Journal of Transplant Surgery · doi:10.36959/338/328
Induction agents and their role in low-immunological-risk kidney transplant recipients
Sathyan, S., Sharma, A., & Halawa, A. M. (2021) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/jesnt.jesnt_12_21
Bird, S. M. (2015) · Wiley eBooks · doi:10.1002/9781118445112.stat05594.pub2
Defining a Steroid Withdrawal Protocol in a newly established Kidney Transplantation Unit
Moyo, O., Kumar, S. A., & Halawa, A. (2017) · Archives of Organ Transplantation · doi:10.17352/2640-7973.000009
Early Medical and Surgical Complications After Kidney Transplantation
Lim, W. H., & Pleass, H. C. C. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch58
Mikulska, M., & Averbuch, D. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_7
Fe de errores de «Recomendaciones para el trasplante renal de donante vivo»
Frutos, M. Á., Crespo, M., Valentín, M. D. L. O., Melgar, Á. A., Alonso, J., Fernández, C., Erauzkin, G. G., González, E., González-Rinne, A. M., Guirado, L., et al. (2023) · Nefrología · doi:10.1016/j.nefro.2023.01.012
Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance
Mannon, E. C., Wood, K. J., & Mannon, R. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00089-7
Seven decades of organ transplantation: Out of the 20th and into the 21st century
Dumbill, R., & Sinha, S. (2024) · Journal of Indira Gandhi Institute Of Medical Sciences · doi:10.4103/jigims.jigims_47_23
Moustafa, B. H., Soliman, N. A., Shaheen, I. S., Badr, A., Atia, F. M., Hatw, M. K. E., Mogahed, E. A., El-Ghamrawy, M., Elkhashab, K., Shaheen, N., et al. (2024) · Egyptian Pediatric Association Gazette · doi:10.1186/s43054-024-00321-y
Transplantation Immunology: Kidney and liver
Trotter, P., McGovern, D., & Clatworthy, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00154-x
Induction Strategies in Heart Transplantation
Stern, L. K., Kransdorf, E. P., & Manla, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-88290-6_13
Dirix, M., Ceuleers, B., & de Fijter, J. W. (2025) · Wiley eBooks · doi:10.1002/9783527847617.ch10
Kashiv, P., Saxena, K., Balwani, M. R., Pasari, A. S., & Kute, V. B. (2026) · World Journal of Transplantation · doi:10.5500/wjt.118000
Brook, M. O. (2026) · Surgery (Oxford) · doi:10.1016/j.mpsur.2026.06.016
Malik, A. K., Banks, J., Counter, C., Simmonds, L., Tingle, S. J., Sinha, S., Muthasamy, A., Sutherland, A., Casey, J., Drage, M. W., et al. (2026) · Transplant International · doi:10.3389/ti.2026.16427
Arepalli, C., & Palani, R. (2026) · Adolescencia e Saude · doi:10.67440/ahj.vi.2850
Metadata
- Authors
- †
- Corresponding author
- †
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 384
- Issue
- 9955
- Pages
- 1684-1690
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2186473865
- Cited by
- 149
- References
- 25
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 8 · 2020: 15 · 2019: 13 · 2018: 17 · 2017: 19 · 2016: 16 · 2015: 17 · 2014: 6
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- Pfizer Ltd and Novartis Pharmaceuticals UK Ltd, and by NHS Blood and Transplant (project reference 09-15-01-03)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Keywords
- alemtuzumab, basiliximab, kidney transplantation, induction therapy, acute rejection, calcineurin inhibitors, tacrolimus, mycophenolate, steroid avoidance, transplant failure, lymphocyte depletion, immunosuppression, renal allograft survival, acute kidney injury, acute tubular necrosis, acute interstitial nephritis
- MeSH terms
- Alemtuzumab, Basiliximab, Adult, Antibodies, Monoclonal, Female, Graft Rejection, Humans, Immunosuppressive Agents, Male, Opportunistic Infections, Recombinant Fusion Proteins, Kidney Transplantation, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
